A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim/Puregon) in healthy female volunteers

Fertility and Sterility

Volumn 73, Issue 6, 2000, Pages 1187-1193

  Voortman, Gerrit ^a   Mannaerts, Bernadette M J L ^a   Huisman, Jan A M ^a  

^a Research and Development   (Netherlands)

Author keywords

Bioequivalence; Dose proportionality; follicular growth; Follistim; intramuscular; pharmacodynamics; pharmacokinetics; Puregon; recombinant FSH; subcutaneous

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL PLUS LYNESTRENOL; FOLLITROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OVARY FOLLICLE DEVELOPMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; OVARIAN FOLLICLE; RECOMBINANT PROTEINS; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 0034086377     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)00542-2     Document Type: Article

References (19)

1. Le Cotonnec J.-Y., Porchet H.C., Beltramy V., Howles C. Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod. 8:1993;1604-1611.
2. Saal W., Glowania H.J., Hengst W., Happ J. Pharmacodynamics and pharmacokinetics after s.c. and i.m. injection of human chorionic gonadotropin. Fertil Steril. 56:1991;225-229.
3. Jones T.H., Darne J.F. Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clin Endocrinol. 38:1993;203-208.
4. Jones T.H., Darne J.F., McGarrigle H.H.G. Diurnal rhythm of testosterone induced by human chorionic gonadotrophin (hCG) therapy in isolated hypogonadotrophic hypogonadism a comparison between subcutaneous and intramuscular HCG administration. Eur J Endocrinol. 131:1994;173-178.
5. Schmoutziguer A.P.E., van Kooij R.J., te Velde E.R., Geurts T.B.P., de Leeuw R., Rombout F. Subcutaneous administration of urinary gonadotrophins - efficacy and safety in in-vitro fertilisation. J Obstet Gynaecol. 16:1996;409-413.
6. Duijkers I.J.M., Klipping C., Mulders T.M.T., Out H.J., Coelingh Bennink H.J.T., Vemer H.M. Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. Hum Reprod. 12:1997;2379-2384.
7. Huisman J.A.M., Paulussen R.J.A., Geurts T.B.P., Odink J., Rekers H. Assessment of bioequivalence after subcutaneous and intramuscular administration of urinary gonadotrophins. Hum Reprod. 12:1997;34-38.
8. Good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol. 67:1990;361-372.
9. Cartwright A.C., et al. International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards. Drug Inform J. 25:1991;471-482.
10. +. Contraception. 14:1976;171-181.
11. Out H.J., Schnabel P.G., Rombout F., Geurts T.B.P., Bosschaert M.A.R., Coelingh Bennink H.J.T. A bioequivalence study of two urinary follicle stimulating hormone preparations Follegon and Metrodin. Hum Reprod. 11:1996;61-63.
12. Voortman G., van de Post J., Schoemaker R.C., van Gerven J.M.A. Bioequivalence of subcutaneous injection of recombinant human FSH (Puregon®) by Pen-injector and syringe. Hum Reprod. 14:1999;1698-1702.
13. Mannaerts B., Fauser B., Lahlou N., Harlin J., Shoham, Coelingh Bennink H., et al. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. Fertil Steril. 65:1996;406-410.
14. Schoot D.C., Harlin J., Shoham Z., Mannaerts B., Lahlou N., Bouchard P., et al. Recombinant human follicle-stimulating hormone and ovarian response in gonadotropin deficient women. Hum Reprod. 9:1994;1237-1242.
15. Dobbs K.E., Dumesic D.A., Dumesic J.A., Shapiro S.S. Differences in serum follicle-stimulating hormone uptake after intramuscular and subcutaneous human menopausal gonadotropin injection. Fertil Steril. 62:1994;978-983.
16. Le Cotonnec J.-Y., Porchet H.C., Beltramy V., Khan A., Toon S., Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril. 61:1994;679-686.
17. Shoham Z., Mannaerts B., Insler V., Coelingh Bennink H. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril. 59:1993;738-742.
18. Balasch J., Miró F., Burzaco I. The role of luteinizing hormone in human follicle development and oocyte fertility evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod. 10:1995;1678-1683.
19. Devroey P., Mannaerts B., Smitz J., Coelingh Bennink H., Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum Reprod. 9:1994;1064-1069.